{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:40:37Z","timestamp":1790743237969,"version":"4.1.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020218","name":"Chiesi USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020218","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12325-024-03062-x","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T08:48:23Z","timestamp":1733388503000},"page":"579-596","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Influence of Treatment Effect Modifiers in Fabry Disease: A Systematic Literature Review"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9226-0544","authenticated-orcid":false,"given":"Khashayar","family":"Azimpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Tordoff-Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Dorling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Koulinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Kunduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Laliman-Khara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Forsythe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"issue":"1","key":"3062_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2019.129437","volume":"1864","author":"JJ Miller","year":"2020","unstructured":"Miller JJ, Kanack AJ, Dahms NM. Progress in the understanding and treatment of Fabry disease. Biochim Biophys Acta Gen Subj. 2020;1864(1): 129437. https:\/\/doi.org\/10.1016\/j.bbagen.2019.129437.","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"3062_CR2","volume-title":"GeneReviews(\u00ae)","author":"A Mehta","year":"2023","unstructured":"Mehta A, Hughes DA, et al. Fabry disease. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, et al., editors. GeneReviews(\u00ae). Seattle: University of Washington; 2023."},{"issue":"6","key":"3062_CR3","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40265-021-01486-1","volume":"81","author":"M Lenders","year":"2021","unstructured":"Lenders M, Brand E. Fabry disease: the current treatment landscape. Drugs. 2021;81(6):635\u201345. https:\/\/doi.org\/10.1007\/s40265-021-01486-1.","journal-title":"Drugs"},{"key":"3062_CR4","unstructured":"National Organization for Rare Disorders (NORD). NORD\u2019s rare disease database: Fabry disease. 2019. https:\/\/rarediseases.org\/rare-diseases\/fabry-disease\/. Accessed on 13 Nov 2023."},{"issue":"1\u20132","key":"3062_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ymgme.2022.07.010","volume":"137","author":"DP Germain","year":"2022","unstructured":"Germain DP, Altarescu G, Barriales-Villa R, Mignani R, Pawlaczyk K, Pieruzzi F, et al. An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease. Mol Genet Metab. 2022;137(1\u20132):49\u201361. https:\/\/doi.org\/10.1016\/j.ymgme.2022.07.010.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"3062_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107692","volume":"140","author":"Y Winter","year":"2023","unstructured":"Winter Y, Hilz M, Beuschlein F, Tsukimura T, Seifritz E, Lenders M, et al. Screening for health-related quality of life and its determinants in Fabry disease: a cross-sectional multicenter study. Mol Genet Metab. 2023;140(3): 107692. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107692.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"3062_CR7","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/ph16020320","volume":"16","author":"M Umer","year":"2023","unstructured":"Umer M, Kalra DK. Treatment of Fabry disease: established and emerging therapies. Pharmaceuticals. 2023;16(2):320.","journal-title":"Pharmaceuticals"},{"key":"3062_CR8","unstructured":"Health Canada. Replagal (agalsidase alfa) approved; issued Notice of Compliance in accordance with the Food and Drug Regulations. 2017. https:\/\/dhpp.hpfb-dgpsa.ca\/review-documents\/resource\/RDS00217. Accessed on 13 Nov 2023."},{"key":"3062_CR9","unstructured":"EMA. Replagal (agalsidase alfa) is authorised for use in the European Union. 2001. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/replagal. Accessed on 30 Aug 2023."},{"issue":"1","key":"3062_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13023-018-0877-4","volume":"13","author":"W Mauhin","year":"2018","unstructured":"Mauhin W, Lidove O, Amelin D, Lamari F, Caillaud C, Mingozzi F, et al. Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY. Orphanet J Rare Dis. 2018;13(1):127. https:\/\/doi.org\/10.1186\/s13023-018-0877-4.","journal-title":"Orphanet J Rare Dis"},{"key":"3062_CR11","unstructured":"PMDA. Replagal (agalsidase alfa) is approved by Pharmaceuticals and Medicals Devices Agency (PMDA) of Japan. 2006. https:\/\/www.pmda.go.jp\/files\/000267893.pdf. Accessed on 30 Aug 2023."},{"key":"3062_CR12","unstructured":"Therapeutic Goods Administration. Replagal (agalsidase alfa) approval: Australian product information. 2010. https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-replagal.pdf. Accessed 30 Jul 2024."},{"key":"3062_CR13","unstructured":"FDA. Fabrazyme (agalsidase beta) approved in the US. 2003. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=15286. Accessed on 30 Aug 2023."},{"key":"3062_CR14","unstructured":"EMA. Fabrazyme (agalsidase beta) is authorised for use in the European Union. 2001. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fabrazyme#authorisation-details-section. Accessed on 30 Aug 2023."},{"key":"3062_CR15","unstructured":"Health Canada. Fabrazyme (agalsidase beta) is approved by Health Canada. 2004. https:\/\/health-products.canada.ca\/dpd-bdpp\/info?lang=eng&code=73340. Accessed on 30 Aug 2023."},{"key":"3062_CR16","unstructured":"PMDA. Fabrazyme (agalsidase beta) is approved by Pharmaceuticals and Medicals Devices Agency (PMDA) of Japan. 2004. https:\/\/www.pmda.go.jp\/files\/000241924.pdf. Accessed on 30 Aug 2023."},{"key":"3062_CR17","unstructured":"Therapeutic Goods Administration. Fabrazyme (agalsidase beta) approval: Australian product information. 2004. https:\/\/www.tga.gov.au\/resources\/artg\/94000. Accessed 30 Jul 2024."},{"key":"3062_CR18","unstructured":"FDA. Approved Elfabrio (pegunigalsidase alfa-iwxj) injection, for intravenous use. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2023\/761161Orig1s000ltr.pdf. Accessed on 30 Aug 2023."},{"key":"3062_CR19","unstructured":"EMA. Elfabrio (pegunigalsidase alfa) is authorised for use in the European Union. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/elfabrio#authorisation-details-section. Accessed on 30 Aug 2023."},{"key":"3062_CR20","unstructured":"Chiesi Farmaceutici S.p.A. ELFABRIO (pegunigalsidase alfa) Summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/elfabrio-epar-product-information_en.pdf. Accessed on 30 Aug 2023."},{"key":"3062_CR21","unstructured":"FDA. Galafold (migalastat) is approved in the US. 2018. https:\/\/www.fda.gov\/drugs\/novel-drug-approvals-fda\/novel-drug-approvals-2018. Accessed on 30 Aug 2023."},{"key":"3062_CR22","unstructured":"EMA. Galafold (migalastat) is authorised for use in the European Union. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/galafold. Accessed on 30 Aug 2023."},{"key":"3062_CR23","unstructured":"PMDA. Japanese Pharmaceuticals and Medical Devices Agency, approval of migalastat hydrochloride. 2018. https:\/\/www.pmda.go.jp\/english\/review-services\/reviews\/approved-information\/drugs\/0001.html. Accessed on 30 Jul 2024."},{"key":"3062_CR24","unstructured":"Therapeutic Goods Administration. Galafold (migalastat) approval: Australian product information. 2018. https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-migalastat-180830-pi.pdf. Accessed 30 Jul 2024."},{"key":"3062_CR25","unstructured":"Health Canada. Galafold (migalastat hydrochloride) approved; issued a notice of compliance in accordance with the Food and Drug Regulations. 2017. https:\/\/dhpp.hpfb-dgpsa.ca\/review-documents\/resource\/RDS00291. Accessed on 13 Nov 2023."},{"issue":"2","key":"3062_CR26","first-page":"203","volume":"1","author":"G Pastores","year":"2004","unstructured":"Pastores G. Agalsidase alfa: enzyme therapy for Anderson\u2013Fabry disease. Therapy. 2004;1(2):203\u201311.","journal-title":"Therapy"},{"key":"3062_CR27","unstructured":"Takeda Pharmaceuticals Intl. REPLALGAL (agalsidase alfa) Summary of product characteristics 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fabrazyme-epar-product-information_en.pdf."},{"issue":"21","key":"3062_CR28","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285(21):2743\u20139. https:\/\/doi.org\/10.1001\/jama.285.21.2743.","journal-title":"JAMA"},{"issue":"1","key":"3062_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/nejm200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human \u03b1-galactosidase a replacement therapy in Fabry\u2019s disease. NEJM. 2001;345(1):9\u201316. https:\/\/doi.org\/10.1056\/nejm200107053450102.","journal-title":"NEJM"},{"issue":"1","key":"3062_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1086\/422366","volume":"75","author":"WR Wilcox","year":"2004","unstructured":"Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet. 2004;75(1):65\u201374. https:\/\/doi.org\/10.1086\/422366.","journal-title":"Am J Hum Genet"},{"issue":"5","key":"3062_CR31","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1681\/asn.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, et al. Sustained, long-term renal stabilization after 54 months of agalsidase \u03b2 therapy in patients with Fabry disease. J Am Soc Nephrol. 2007;18(5):1547\u201357. https:\/\/doi.org\/10.1681\/asn.2006080816.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"3062_CR32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","volume":"52","author":"DP Germain","year":"2015","unstructured":"Germain DP, Charrow J, Desnick RJ, Guffon N, Kempf J, Lachmann RH, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015;52(5):353\u20138. https:\/\/doi.org\/10.1136\/jmedgenet-2014-102797.","journal-title":"J Med Genet"},{"issue":"2","key":"3062_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","volume":"146","author":"M Banikazemi","year":"2007","unstructured":"Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007;146(2):77\u201386. https:\/\/doi.org\/10.7326\/0003-4819-146-2-200701160-00148.","journal-title":"Ann Intern Med"},{"issue":"6","key":"3062_CR34","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, et al. Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat. N Engl J Med. 2016;375(6):545\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1510198.","journal-title":"N Engl J Med"},{"issue":"4","key":"3062_CR35","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","volume":"54","author":"DA Hughes","year":"2017","unstructured":"Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet. 2017;54(4):288\u201396. https:\/\/doi.org\/10.1136\/jmedgenet-2016-104178.","journal-title":"J Med Genet"},{"issue":"6","key":"3062_CR36","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1136\/jmg-2023-109445","volume":"61","author":"EL Wallace","year":"2024","unstructured":"Wallace EL, Goker-Alpan O, Wilcox WR, Holida M, Bernat J, Longo N, et al. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study. J Med Genet. 2024;61(6):520\u201330. https:\/\/doi.org\/10.1136\/jmg-2023-109445.","journal-title":"J Med Genet"},{"issue":"1","key":"3062_CR37","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s13023-023-02937-6","volume":"18","author":"A Linhart","year":"2023","unstructured":"Linhart A, Dost\u00e1lov\u00e1 G, Nicholls K, West ML, T\u00f8ndel C, Jovanovic A, et al. Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study. Orphanet J Rare Dis. 2023;18(1):332. https:\/\/doi.org\/10.1186\/s13023-023-02937-6.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"3062_CR38","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1016\/j.gim.2022.01.185","volume":"24","author":"J Bernat","year":"2022","unstructured":"Bernat J, Holida M, Longo N, Goker-Alpan O, Wallace SE, Deegan P, et al. eP149: safety and efficacy of pegunigalsidase alfa, every 4 weeks, in Fabry disease: results from the phase 3, open-label BRIGHT study. Genet Med. 2022;24(3):S91\u20132.","journal-title":"Genet Med"},{"issue":"7","key":"3062_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000598","volume":"2","author":"AC Vedder","year":"2007","unstructured":"Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ, et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg. PLoS ONE. 2007;2(7): e598. https:\/\/doi.org\/10.1371\/journal.pone.0000598.","journal-title":"PLoS ONE"},{"issue":"3","key":"3062_CR40","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","volume":"94","author":"AC Vedder","year":"2008","unstructured":"Vedder AC, Breunig F, Donker-Koopman WE, Mills K, Young E, Winchester B, et al. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab. 2008;94(3):319\u201325. https:\/\/doi.org\/10.1016\/j.ymgme.2008.03.003.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"3062_CR41","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","volume":"111","author":"SM Sirrs","year":"2014","unstructured":"Sirrs SM, Bichet DG, Casey R, Clarke JT, Lemoine K, Doucette S, et al. Outcomes of patients treated through the Canadian Fabry disease initiative. Mol Genet Metab. 2014;111(4):499\u2013506. https:\/\/doi.org\/10.1016\/j.ymgme.2014.01.014.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"3062_CR42","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/gim.2016.117","volume":"19","author":"A Pisani","year":"2017","unstructured":"Pisani A, Bruzzese D, Sabbatini M, Spinelli L, Imbriaco M, Riccio E. Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature. Genet Med. 2017;19(3):275\u201382. https:\/\/doi.org\/10.1038\/gim.2016.117.","journal-title":"Genet Med"},{"issue":"4 suppl","key":"3062_CR43","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1590\/s1415-47572012000600009","volume":"35","author":"T Alegra","year":"2012","unstructured":"Alegra T, Vairo F, de Souza MV, Krug BC, Schwartz IV. Enzyme replacement therapy for Fabry disease: a systematic review and meta-analysis. Genet Mol Biol. 2012;35(4 suppl):947\u201354. https:\/\/doi.org\/10.1590\/s1415-47572012000600009.","journal-title":"Genet Mol Biol"},{"issue":"5","key":"3062_CR44","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/jmedgenet-2017-104863","volume":"55","author":"M Arends","year":"2018","unstructured":"Arends M, Biegstraaten M, Wanner C, Sirrs S, Mehta A, Elliott PM, et al. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. J Med Genet. 2018;55(5):351\u20138. https:\/\/doi.org\/10.1136\/jmedgenet-2017-104863.","journal-title":"J Med Genet"},{"issue":"7","key":"3062_CR45","doi-asserted-by":"publisher","first-page":"Cd006663","DOI":"10.1002\/14651858.CD006663.pub4","volume":"7","author":"R El Dib","year":"2016","unstructured":"El Dib R, Gomaa H, Carvalho RP, Camargo SE, Bazan R, Barretti P, et al. Enzyme replacement therapy for Anderson\u2013Fabry disease. Cochrane Database Syst Rev. 2016;7(7):Cd006663. https:\/\/doi.org\/10.1002\/14651858.CD006663.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"3062_CR46","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1093\/ckj\/sfaa065","volume":"14","author":"A Ortiz","year":"2021","unstructured":"Ortiz A, Kanters S, Hamed A, DasMahapatra P, Poggio E, Maski M, et al. Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis. Clin Kidney J. 2021;14(4):1136\u201346. https:\/\/doi.org\/10.1093\/ckj\/sfaa065.","journal-title":"Clin Kidney J"},{"issue":"3","key":"3062_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173358","volume":"12","author":"R El Dib","year":"2017","unstructured":"El Dib R, Gomaa H, Ortiz A, Politei J, Kapoor A, Barreto F. Enzyme replacement therapy for Anderson\u2013Fabry disease: a complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. PLoS ONE. 2017;12(3): e0173358. https:\/\/doi.org\/10.1371\/journal.pone.0173358.","journal-title":"PLoS ONE"},{"issue":"47","key":"3062_CR48","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3238\/arztebl.2015.0803","volume":"112","author":"C Kiefer","year":"2015","unstructured":"Kiefer C, Sturtz S, Bender R. Indirect comparisons and network meta-analyses. Dtsch Arztebl Int. 2015;112(47):803\u20138. https:\/\/doi.org\/10.3238\/arztebl.2015.0803.","journal-title":"Dtsch Arztebl Int"},{"issue":"9","key":"3062_CR49","doi-asserted-by":"publisher","first-page":"723","DOI":"10.2165\/11535670-000000000-00000","volume":"28","author":"M Coory","year":"2010","unstructured":"Coory M, Jordan S. Frequency of treatment-effect modification affecting indirect comparisons: a systematic review. Pharmacoeconomics. 2010;28(9):723\u201332. https:\/\/doi.org\/10.2165\/11535670-000000000-00000.","journal-title":"Pharmacoeconomics"},{"key":"3062_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"3062_CR51","unstructured":"NICE. The guidelines manual: process and methods [PMG6]. 2012."},{"issue":"4","key":"3062_CR52","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1017\/S0266462310000978","volume":"26","author":"A Booth","year":"2010","unstructured":"Booth A, Wright K, Outhwaite H. Centre for reviews and dissemination databases: value, content, and developments. Int J Technol Assess Health Care. 2010;26(4):470\u20132.","journal-title":"Int J Technol Assess Health Care"},{"issue":"2","key":"3062_CR53","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ymgme.2017.05.001","volume":"121","author":"M Arends","year":"2017","unstructured":"Arends M, Wijburg FA, Wanner C, Vaz FM, van Kuilenburg ABP, Hughes DA, et al. Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease. Mol Genet Metab. 2017;121(2):157\u201361. https:\/\/doi.org\/10.1016\/j.ymgme.2017.05.001.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"3062_CR54","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1017\/thg.2017.46","volume":"20","author":"D Hughes","year":"2017","unstructured":"Hughes D, Linhart A, Gurveich A, Joseph A, Kerstens R, Feriozzi S. Prompt agalsidase afa therapy initiation is associated with improved outcomes in the Fabry Outcome Survey. Twin Res Hum Genet. 2017;20(5):425\u201345.","journal-title":"Twin Res Hum Genet"},{"issue":"1","key":"3062_CR55","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1016\/j.ymgme.2016.11.208","volume":"120","author":"A Linhart","year":"2017","unstructured":"Linhart A, Hughes D, Gurevich A, Joseph A, Kerstens R, Feriozzi S. Prompt agalsidase alfa therapy initiation after symptom onset is associated with improved renal and cardiovascular outcomes in the Fabry Outcome Survey. Mol Genet Metab. 2017;120(1):S85. https:\/\/doi.org\/10.1016\/j.ymgme.2016.11.208.","journal-title":"Mol Genet Metab"},{"key":"3062_CR56","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.2147\/dddt.S313789","volume":"15","author":"D Hughes","year":"2021","unstructured":"Hughes D, Linhart A, Gurevich A, Kalampoki V, Jazukeviciene D, Feriozzi S. Prompt agalsidase alfa therapy initiation is associated with improved renal and cardiovascular outcomes in a Fabry Outcome Survey analysis. Drug Des Devel Ther. 2021;15:3561\u201372. https:\/\/doi.org\/10.2147\/dddt.S313789.","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"3062_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2022.107273","volume":"138","author":"GP Morell","year":"2023","unstructured":"Morell GP, Kampmann C, Botha J, Anagnostopoulou C, West ML, Ramaswami U. Early initiation of agalsidase alfa treatment improves clinical outcomes in male patients with classical Fabry disease: a Fabry Outcome Survey (FOS) analysis. Mol Genet Metab. 2023;138(2): 107273. https:\/\/doi.org\/10.1016\/j.ymgme.2022.107273.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3062_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000464312","volume":"42","author":"A Nowak","year":"2017","unstructured":"Nowak A, Koch G, Huynh-Do U, Siegenthaler M, Marti HP, Pfister M. Disease progression modeling to evaluate the effects of enzyme replacement therapy on kidney function in adult patients with the classic phenotype of Fabry disease. Kidney Blood Press Res. 2017;42(1):1\u201315. https:\/\/doi.org\/10.1159\/000464312.","journal-title":"Kidney Blood Press Res"},{"key":"3062_CR59","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.2147\/dddt.S207856","volume":"13","author":"U Ramaswami","year":"2019","unstructured":"Ramaswami U, Beck M, Hughes D, Kampmann C, Botha J, Pintos-Morell G, et al. Cardio-renal outcomes with long-term agalsidase alfa enzyme replacement therapy: a 10-year Fabry Outcome Survey (FOS) analysis. Drug Des Dev Therapy. 2019;13:3705\u201315. https:\/\/doi.org\/10.2147\/dddt.S207856.","journal-title":"Drug Des Dev Therapy"},{"issue":"3","key":"3062_CR60","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/ehjcvp\/pvab025","volume":"8","author":"M Lenders","year":"2022","unstructured":"Lenders M, Nordbeck P, Kurschat C, Eveslage M, Karabul N, Kaufeld J, et al. Treatment of Fabry disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS). Eur Heart J Cardiovasc Pharmacother. 2022;8(3):272\u201381. https:\/\/doi.org\/10.1093\/ehjcvp\/pvab025.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"12","key":"3062_CR61","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1016\/j.clinthera.2020.10.007","volume":"42","author":"S Feriozzi","year":"2020","unstructured":"Feriozzi S, Linhart A, Ramaswami U, Kalampoki V, Gurevich A, Hughes D. Effects of baseline left ventricular hypertrophy and decreased renal function on cardiovascular and renal outcomes in patients with Fabry disease treated with agalsidase alfa: a Fabry Outcome Survey study. Clin Ther. 2020;42(12):2321-30.e0. https:\/\/doi.org\/10.1016\/j.clinthera.2020.10.007.","journal-title":"Clin Ther"},{"key":"3062_CR62","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1177\/2326409817722292","volume":"5","author":"S Feriozzi","year":"2017","unstructured":"Feriozzi S, Linhart A, Ramaswami U, Gurevich A, Joseph A, Kerstens R, et al. 800\u2014Left ventricular hypertrophy and decreased renal function at baseline predict worse cardiovascular and renal outcomes in patients in the FOS Registry. J Inborn Errors Metab Screen. 2017;5:360. https:\/\/doi.org\/10.1177\/2326409817722292.","journal-title":"J Inborn Errors Metab Screen."},{"issue":"4","key":"3062_CR63","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/ehf2.12712","volume":"7","author":"F Graziani","year":"2020","unstructured":"Graziani F, Lillo R, Panaioli E, Pieroni M, Camporeale A, Verrecchia E, et al. Prognostic significance of right ventricular hypertrophy and systolic function in Anderson\u2013Fabry disease. ESC Heart Fail. 2020;7(4):1605\u201314. https:\/\/doi.org\/10.1002\/ehf2.12712.","journal-title":"ESC Heart Fail"},{"key":"3062_CR64","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ijcard.2017.09.027","volume":"249","author":"M Siegenthaler","year":"2017","unstructured":"Siegenthaler M, Huynh-Do U, Krayenbuehl P, Pollock E, Widmer U, Debaix H, et al. Impact of cardio-renal syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up. Int J Cardiol. 2017;249:261\u20137. https:\/\/doi.org\/10.1016\/j.ijcard.2017.09.027.","journal-title":"Int J Cardiol"},{"issue":"8","key":"3062_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182379","volume":"12","author":"M Arends","year":"2017","unstructured":"Arends M, Biegstraaten M, Hughes DA, Mehta A, Elliott PM, Oder D, et al. Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: analysis of prognostic factors. PLoS ONE. 2017;12(8): e0182379. https:\/\/doi.org\/10.1371\/journal.pone.0182379.","journal-title":"PLoS ONE"},{"issue":"6","key":"3062_CR66","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.nefroe.2022.01.003","volume":"41","author":"M Goicoechea","year":"2021","unstructured":"Goicoechea M, Gomez-Preciado F, Benito S, Torras J, Torra R, Huerta A, et al. Predictors of outcome in a Spanish cohort of patients with Fabry disease on enzyme replacement therapy. Nefrologia (Engl Ed). 2021;41(6):652\u201360. https:\/\/doi.org\/10.1016\/j.nefroe.2022.01.003.","journal-title":"Nefrologia (Engl Ed)"},{"issue":"12","key":"3062_CR67","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1093\/ndt\/gfw334","volume":"32","author":"M Lenders","year":"2017","unstructured":"Lenders M, Schmitz B, Stypmann J, Duning T, Brand SM, Kurschat C, et al. Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease. Nephrol Dial Transplant. 2017;32(12):2090\u20137. https:\/\/doi.org\/10.1093\/ndt\/gfw334.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"3062_CR68","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/ndt\/gfr420","volume":"27","author":"DG Warnock","year":"2012","unstructured":"Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, Serra AL, et al. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant. 2012;27(3):1042\u20139. https:\/\/doi.org\/10.1093\/ndt\/gfr420.","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"3062_CR69","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.2215\/cjn.04340510","volume":"5","author":"C Wanner","year":"2010","unstructured":"Wanner C, Oliveira JP, Ortiz A, Mauer M, Germain DP, Linthorst GE, et al. Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clin J Am Soc Nephrol. 2010;5(12):2220\u20138. https:\/\/doi.org\/10.2215\/cjn.04340510.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"3062_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2022.106967","volume":"138","author":"RJ Hopkin","year":"2023","unstructured":"Hopkin RJ, Cabrera GH, Jefferies JL, Yang M, Ponce E, Brand E, et al. Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: an analysis from the Fabry Registry. Mol Genet Metab. 2023;138(2): 106967. https:\/\/doi.org\/10.1016\/j.ymgme.2022.106967.","journal-title":"Mol Genet Metab"},{"key":"3062_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11164810","author":"M Cybulla","year":"2022","unstructured":"Cybulla M, Nicholls K, Feriozzi S, Linhart A, Torras J, Vujkovac B, et al. Renoprotective effect of agalsidase alfa: a long-term follow-up of patients with Fabry disease. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11164810.","journal-title":"J Clin Med"},{"issue":"2","key":"3062_CR72","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1016\/j.ymgme.2019.11.321","volume":"129","author":"C Orsborne","year":"2020","unstructured":"Orsborne C, Thompson L, Jovanovic A. Migalastat therapy for Fabry disease; real-word clinical outcomes comparing those previously treated with ERT with those who are treatment naive. Mol Genet Metab. 2020;129(2):S123. https:\/\/doi.org\/10.1016\/j.ymgme.2019.11.321.","journal-title":"Mol Genet Metab"},{"issue":"12","key":"3062_CR73","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1681\/asn.2018070740","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Neu\u00dfer LP, Rudnicki M, Nordbeck P, Canaan-K\u00fchl S, Nowak A, et al. Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with Fabry disease. J Am Soc Nephrol. 2018;29(12):2879\u201389. https:\/\/doi.org\/10.1681\/asn.2018070740.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3062_CR74","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1681\/asn.2014121226","volume":"27","author":"M Lenders","year":"2016","unstructured":"Lenders M, Stypmann J, Duning T, Schmitz B, Brand SM, Brand E. Serum-mediated inhibition of enzyme replacement therapy in Fabry disease. J Am Soc Nephrol. 2016;27(1):256\u201364. https:\/\/doi.org\/10.1681\/asn.2014121226.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"3062_CR75","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ymgme.2018.11.008","volume":"126","author":"SJ van der Veen","year":"2019","unstructured":"van der Veen SJ, van Kuilenburg ABP, Hollak CEM, Kaijen PHP, Voorberg J, Langeveld M. Antibodies against recombinant alpha-galactosidase A in Fabry disease: subclass analysis and impact on response to treatment. Mol Genet Metab. 2019;126(2):162\u20138. https:\/\/doi.org\/10.1016\/j.ymgme.2018.11.008.","journal-title":"Mol Genet Metab"},{"issue":"10","key":"3062_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047805","volume":"7","author":"SM Rombach","year":"2012","unstructured":"Rombach SM, Aerts JM, Poorthuis BJ, Groener JE, Donker-Koopman W, Hendriks E, et al. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS ONE. 2012;7(10): e47805. https:\/\/doi.org\/10.1371\/journal.pone.0047805.","journal-title":"PLoS ONE"},{"issue":"1","key":"3062_CR77","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13023-024-03131-y","volume":"19","author":"A Jovanovic","year":"2024","unstructured":"Jovanovic A, Miller-Hodges E, Castriota F, Takyar S, Howitt H, Ayodele O. A systematic literature review on the health-related quality of life and economic burden of Fabry disease. Orphanet J Rare Dis. 2024;19(1):181. https:\/\/doi.org\/10.1186\/s13023-024-03131-y.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3062_CR78","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1148\/radiol.2019191385","volume":"294","author":"K Hanneman","year":"2020","unstructured":"Hanneman K, Karur GR, Wasim S, Wald RM, Iwanochko RM, Morel CF. Left ventricular hypertrophy and late gadolinium enhancement at cardiac MRI are associated with adverse cardiac events in Fabry disease. Radiology. 2020;294(1):42\u20139. https:\/\/doi.org\/10.1148\/radiol.2019191385.","journal-title":"Radiology"},{"issue":"4","key":"3062_CR79","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s10554-020-02105-y","volume":"37","author":"L Spinelli","year":"2021","unstructured":"Spinelli L, Giugliano G, Pisani A, Imbriaco M, Riccio E, Russo C, et al. Does left ventricular function predict cardiac outcome in Anderson\u2013Fabry disease? Int J Cardiovasc Imaging. 2021;37(4):1225\u201336. https:\/\/doi.org\/10.1007\/s10554-020-02105-y.","journal-title":"Int J Cardiovasc Imaging"},{"issue":"9","key":"3062_CR80","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","volume":"57","author":"MR Patel","year":"2011","unstructured":"Patel MR, Cecchi F, Cizmarik M, Kantola I, Linhart A, Nicholls K, et al. Cardiovascular events in patients with Fabry disease natural history data from the Fabry registry. J Am Coll Cardiol. 2011;57(9):1093\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2010.11.018.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"3062_CR81","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989x17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200\u201311. https:\/\/doi.org\/10.1177\/0272989x17725740.","journal-title":"Med Decis Making"},{"issue":"3","key":"3062_CR82","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ymgme.2018.04.004","volume":"126","author":"C Wanner","year":"2019","unstructured":"Wanner C, Germain DP, Hilz MJ, Spada M, Falissard B, Elliott PM. Therapeutic goals in Fabry disease: recommendations of a European expert panel, based on current clinical evidence with enzyme replacement therapy. Mol Genet Metab. 2019;126(3):210\u20131. https:\/\/doi.org\/10.1016\/j.ymgme.2018.04.004.","journal-title":"Mol Genet Metab"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03062-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03062-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03062-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T10:54:44Z","timestamp":1738407284000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03062-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":82,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3062"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03062-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"24 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Khashayar Azimpour, Patricia Dorling, Irene Koulinska, and Swati Kunduri are employees of Chiesi. Carla Tordoff-Gibson, Victor Laliman-Khara, and Anna Forsythe * are employees of Cytel Inc.; Chiesi commissioned Cytel Inc. for the study design, analysis, and development of the manuscript. *Affiliation at the time of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors and the data are not identifiable. Further the data from the databases used in the searches is not identifiable. Therefore, Ethics committee approval was not required for this study. The systematic literature review used the following publicly available databases: Ovid platform: . Medline: . Embase: . Econlit: . Cochrane: .","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}